A clinical study performed by Wieser et al. in 2014, investigated the biodistribution, dosimetry, and tumor uptake of the GRPR antagonist 64Cu-CB-TE2A-AR06 by PET/CT in 4 patients with newly diagnosed prostate cancer [41]. This evidence concerns the gene GRPR and prostate carcinoma.